Month: Nov 2021
Pfizer Anti-Viral & Ivermectin Science Based Comparison
So Pfizer has created a new anti-Covid drug which does the same as Ivermectin… which is free from patent (cost 6 cents), but is patented by Pfizer (cost $300)… which will earn them a fortune. I wonder why Pfizer, and MSM et al, spent so much time telling people to ignore Ivermectin while Pfizer developed their own patented version?
Natural Immunity protects from reinfection and spreading
In response to a request made under the Freedom of Information Act (FOI) the U.S. Centers for Disease Control & Prevention (“CDC”) admitted it does not have any documented cases of unvaccinated people being re-infected or transmitting Covid to another person after acquiring natural immunity.
Stop the harm to the children
Keep this on the record as you allow your kids to be infected with the vaccine. You’re risking their health… they have a longer future than you, you’re cutting it shorter, less healthy…
REMEMBER, NO KIDS HAVE GOT SICK LIKE THIS YET. DO YOU WANT TO BEGIN THE HORRIBLE STATISTIC? DO YOU WANT TO MAKE YOUR KID THE FIRST.
MATH+ Hospital Treatment Protocol for COVID-19
via FLCCC ALLIANCE
The MATH+ Hospital Treatment Protocol for COVID-19 is designed for hospitalized patients, to be initiated as soon as possible after they develop respiratory difficulty and require oxygen supplementation. The three core pathophysiologic processes that have been identified are severe hypoxemia, hyperinflammation, and hypercoagulability. This combination medication protocol is designed to counteract these processes either through the use of single agents or in synergistic actions. A unique insight into this disease made by members of our group is that the majority of patients initially present with an inflammatory reaction in the lungs called “organizing pneumonia,” which is the body’s reaction to injury and is profoundly responsive to corticosteroid therapy. If the organizing pneumonia response is left untreated or presents as a rapidly progressive sub-type, a condition called Acute Respiratory Distress Syndrome (ARDS) follows.
The two main therapies that can reverse and/or mitigate the extreme inflammation causing ARDS are the combination of the corticosteroid Methylprednisolone and the antioxidant Ascorbic acid, which is given intravenously and in high doses. Both of these medicines have multiple synergistic physiologic effects and have been shown in multiple randomized controlled trials to improve survival in ARDS, particularly when given early in the disease. Thiamine is given to optimize cellular oxygen utilization and energy consumption, protecting the heart, brain, and immune system. Given the numerous clinical and scientific investigations that have demonstrated consistent, reproducible, and excessive levels of hyper-coagulation, particularly in the severely ill, the anticoagulant Heparin is used to both prevent and help in dissolving blood clots that appear with a very high frequency. The “+” sign indicates several important co-interventions that have a combination of strong physiologic rationale with existing or emerging pre-clinical and clinical data to support their use in similar conditions or in COVID-19 itself, and all with a well-established safety profile. Such adjunctive therapies are continuously being evaluated and amended as the published medical evidence evolves.